Cellulitis, Erysipelas or Bacterial Lymphangitis: Complete ICD-11 Coding Guide (1B70)

1. Introduction

Bacterial infections of the skin and soft tissues represent one of the most frequent causes of medical care seeking in emergency departments and outpatient clinics worldwide. Among these infections, cellulitis, erysipelas, and bacterial lymphangitis constitute an important group of conditions that, although sharing similar pathophysiological mechanisms, present distinct clinical characteristics that determine their management and prognosis.

Cellulitis is characterized by a deep infection of the dermis and subcutaneous tissue, while erysipelas is a more superficial infection that predominantly affects the upper dermis and superficial lymphatic vessels. Bacterial lymphangitis, in turn, represents inflammation of the lymphatic vessels caused by the dissemination of bacteria through the lymphatic system. These conditions are caused mainly by beta-hemolytic streptococci of group A and Staphylococcus aureus, although other organisms may be involved in specific situations.

The clinical importance of these infections cannot be underestimated. When not treated adequately, they can progress to serious complications such as abscess, necrotizing fasciitis, sepsis, and even death. The prevalence of these conditions is significant in populations of all ages, with particularly high incidence in patients with risk factors such as diabetes mellitus, obesity, chronic venous insufficiency, and immunodeficiencies.

From a public health perspective, these infections represent substantial costs due to hospitalizations, prolonged antibiotic treatment, and loss of productivity. Correct coding of these conditions is critical for epidemiological monitoring, resource allocation, health policy planning, and ensuring adequate reimbursement in health systems. The transition to ICD-11 offers greater specificity and clarity in the classification of these infections, facilitating communication among health professionals and improving the quality of global health data.

2. Correct ICD-11 Code

Code: 1B70

Description: Cellulitis, erysipelas or bacterial lymphangitis

Parent category: Pyogenic bacterial infections of skin or subcutaneous tissue

Official definition: Diffuse and disseminated infections of the skin and soft tissues by a variety of bacterial organisms, most commonly beta-hemolytic streptococci and Staphylococcus aureus. The clinical presentation depends not only on the organism, but also on the manner in which it invades the tissues.

This code is positioned within the hierarchical structure of ICD-11 as part of bacterial infections that affect the skin and subcutaneous structures. The classification 1B70 groups three related clinical entities that share similar pathogenic mechanisms, but differ in depth of tissue invasion and clinical presentation.

Coding under 1B70 allows for comprehensive identification of diffuse bacterial infections of the skin that do not present characteristics of other more specific conditions such as necrotizing fasciitis, impetigo or ecthyma. This categorization facilitates epidemiological analysis and monitoring of trends in bacterial resistance, in addition to enabling comparative studies on the effectiveness of different therapeutic approaches.

It is important to note that code 1B70 has subcategories that allow for greater specificity when necessary, reflecting the evolution of the international classification of diseases toward more detailed and clinically relevant coding.

3. When to Use This Code

The code 1B70 should be used in specific clinical situations where there is clear evidence of diffuse bacterial infection of the skin and soft tissues. Below, we present detailed practical scenarios:

Scenario 1: Cellulitis of lower limb in patient with portal of entry A patient presents with an area of erythema, edema, warmth, and pain in the right leg, with poorly defined borders, following minor cutaneous trauma that occurred three days prior. There is fever of 38.5°C and the affected area extends progressively. Examination reveals diffuse erythema without crepitus or hemorrhagic bullae. In this case, code 1B70 is appropriate as it characterizes typical cellulitis without signs of necrotizing infection.

Scenario 2: Facial erysipelas with raised borders A patient develops an erythematous plaque on the face, with well-demarcated and raised borders, accompanied by high fever and malaise. The lesion has a shiny appearance and is warm to the touch, limited to the superficial dermis without deep involvement. The classic presentation of erysipelas justifies the use of code 1B70, distinguishing it from other skin infections.

Scenario 3: Ascending lymphangitis post-wound Following a penetrating wound to a finger, a patient develops ascending red lines on the forearm, following the course of lymphatic vessels, accompanied by painful regional lymphadenopathy and fever. This presentation of acute bacterial lymphangitis is appropriately coded as 1B70.

Scenario 4: Recurrent cellulitis in limb with chronic lymphedema A patient with chronic lymphedema of the lower limb presents with an acute episode of cellulitis, with diffuse erythema, edema in addition to the pre-existing edema, pain, and fever. The history of similar previous episodes does not exclude the use of code 1B70 for the current episode.

Scenario 5: Periorbital cellulitis without intraorbital involvement A child develops edema, erythema, and warmth in the eyelid and periorbital region, without signs of vision compromise, preserved ocular motility, and without proptosis. Imaging studies rule out orbital cellulitis. The presentation of periorbital cellulitis is coded as 1B70.

Scenario 6: Erysipelas in upper limb with history of mastectomy A patient who underwent mastectomy with axillary lymphadenectomy develops erysipelas in the ipsilateral upper limb, presenting with a well-demarcated, warm, and painful erythematous plaque. The presence of a predisposing factor (lymphatic compromise) does not alter the coding as 1B70.

In all these scenarios, essential criteria must be present: evidence of bacterial infection (fever, leukocytosis, local inflammatory signs), diffuse cutaneous involvement without characteristics of necrotizing infection, and absence of localized abscess formation or other characteristics that would indicate alternative codes.

4. When NOT to Use This Code

It is essential to recognize situations where code 1B70 is not appropriate, avoiding coding errors that may compromise epidemiological and administrative data.

Eosinophilic cellulitis (Wells Syndrome): This condition should be coded as 1860796142. Unlike common bacterial cellulitis, eosinophilic cellulitis is a non-infectious inflammatory condition characterized by eosinophilic infiltration of the dermis and subcutaneous tissue. Patients present with erythematous and edematous plaques, but without evidence of bacterial infection, with biopsy showing characteristic eosinophilic infiltrate.

Necrotizing fasciitis: When there are signs of progressive tissue necrosis, crepitus on palpation, hemorrhagic bullae, pain disproportionate to physical examination, or rapid clinical deterioration despite adequate antibiotic therapy, the appropriate code is 1B71, not 1B70. Necrotizing fasciitis is a surgical emergency requiring immediate differentiation.

Impetigo: Superficial infections characterized by vesicles and honey-crusted lesions, without deep dermal involvement, should be coded as 1B72. Impetigo is typically an epidermal infection, whereas 1B70 refers to deeper infections.

Ecthyma: Cutaneous ulcers with adherent crusts and raised borders, penetrating the dermis, are coded as 1B73. Although caused by similar bacteria, the ulcerated presentation distinguishes ecthyma from diffuse cellulitis.

Localized cutaneous abscesses: Well-demarcated purulent collections require specific codes for abscesses, not 1B70. The presence of fluctuance and need for surgical drainage indicate abscess, not diffuse cellulitis.

Fungal or viral infections: Conditions such as herpes zoster or deep fungal infections may mimic cellulitis, but require specific codes for their etiologies.

Non-infectious inflammatory conditions: Stasis dermatitis, superficial thrombophlebitis, erythema nodosum, and other inflammatory conditions without an infectious component should not be coded as 1B70, even when presenting with erythema and edema.

Proper differentiation requires careful clinical evaluation, considering history, complete physical examination, and when necessary, complementary tests such as complete blood count, inflammatory markers, cultures, and imaging studies.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The diagnosis of cellulitis, erysipelas, or bacterial lymphangitis is primarily clinical. Begin by evaluating the essential criteria:

Local manifestations: Presence of erythema (redness), edema (swelling), local warmth, and pain. In cellulitis, borders are poorly defined and diffuse; in erysipelas, borders are raised and well demarcated; in lymphangitis, red linear streaks are observed following the lymphatic pathway.

Systemic manifestations: Fever, chills, general malaise, and regional lymphadenopathy are common, although not always present, especially in elderly or immunocompromised patients.

Assessment tools: Perform complete blood count (leukocytosis with left shift is common), C-reactive protein, and erythrocyte sedimentation rate (elevated in most cases). Blood cultures should be considered in patients with severe systemic signs, although the yield is relatively low.

Identification of portal of entry: Look for breaks in skin continuity such as wounds, interdigital fissures, insect bites, or pre-existing dermatoses.

Evaluation of predisposing factors: Identify diabetes mellitus, obesity, venous insufficiency, lymphedema, use of immunosuppressants, or other conditions that increase risk.

Step 2: Verify Specifiers

After confirming the diagnosis, evaluate characteristics that may require additional specification:

Anatomical location: Lower extremities are most frequently affected, but face, upper extremities, and trunk can also be involved. Location may influence differential diagnoses.

Severity: Classify as mild (no systemic signs, limited area), moderate (systemic signs present, extensive area), or severe (signs of sepsis, organ failure).

Laterality: Specify whether unilateral or bilateral (rare, but can occur).

Recurrence: Document whether it is the first episode or recurrent, as recurrent cellulitis may require additional investigation of predisposing factors.

Step 3: Differentiate from Other Codes

1B71 - Necrotizing fasciitis: The key difference is the presence of progressive tissue necrosis. Warning signs include pain disproportionate to examination findings, crepitus (indicating gas production), hemorrhagic bullae, rapid progression despite antibiotics, skin changes such as violaceous or grayish discoloration, and severe systemic toxicity. Necrotizing fasciitis is a surgical emergency requiring immediate debridement.

1B72 - Impetigo: The main difference lies in depth and presentation. Impetigo is superficial, affecting only the epidermis, presenting with vesicles that rupture forming meliceric crusts (honey-colored). There is no deep involvement or significant systemic signs. It is more common in children and highly contagious.

1B73 - Ecthyma: Distinguished by the formation of ulcers with adherent crusts and raised borders. Ecthyma penetrates more deeply than impetigo but presents with localized and well-defined lesions, unlike diffuse cellulitis. Ecthyma ulcers leave scars after resolution.

Step 4: Necessary Documentation

For adequate coding, medical documentation should include:

Checklist of mandatory information:

Detailed description of skin lesions (location, extent, border characteristics)
Presence or absence of systemic signs (fever, heart rate, blood pressure)
Identification of portal of entry when possible
Risk factors and relevant comorbidities
Results of laboratory tests performed
Differential diagnoses considered and excluded
Specific classification (cellulitis, erysipelas, or lymphangitis)
Severity of clinical presentation
Therapeutic plan instituted

Adequate documentation: Use standardized medical terminology, avoid vague descriptions such as "redness on the leg". Prefer "diffuse erythema in the middle and distal third of the right leg, with poorly defined borders, measuring approximately 15x10 cm, associated with edema and local warmth, without crepitus or bullae".

6. Complete Practical Example

Clinical Case

A 58-year-old female patient presents to the emergency department with complaints of pain and swelling in the left leg for two days. She reports that four days ago she sustained a small wound while walking barefoot in the garden, which she cleaned superficially at home. Forty-eight hours ago she noticed redness and local warmth that has been progressively expanding, accompanied by increasing pain and fever (measured 38.2°C at home).

Medical history: Type 2 diabetes mellitus on metformin therapy, obesity (BMI 32), controlled arterial hypertension.

Physical examination: Patient in fair general condition, febrile (axillary temperature 38.5°C), heart rate 98 bpm, blood pressure 140/85 mmHg. On examination of the left lower extremity, a diffuse erythematous area with poorly defined borders is observed, extending from the ankle to the middle third of the leg, measuring approximately 20x15 cm. There is local edema, warmth on palpation, and pain on compression. Small abrasion of 0.5 cm on the dorsum of the foot with signs of re-epithelialization. No crepitus, bullae, or areas of necrosis. Peripheral pulses preserved. Palpable and tender left inguinal lymphadenopathy.

Complementary tests ordered:

Complete blood count: leukocytes 14,500/mm³ with 82% neutrophils, without significant left shift
C-reactive protein: 85 mg/L (reference value <5 mg/L)
Blood glucose: 165 mg/dL
Renal function: normal
Blood cultures: collected (two samples)

Diagnostic reasoning: The clinical presentation is compatible with bacterial cellulitis of the left lower extremity. The presence of an identifiable portal of entry (foot abrasion), diffuse erythema with poorly defined borders, signs of local inflammation (warmth, edema, pain), regional lymphadenopathy, and systemic manifestations (fever, leukocytosis, elevated CRP) confirm the diagnosis. The patient presents with important risk factors (diabetes, obesity) that predispose to infection.

Differential diagnoses considered and excluded:

Deep venous thrombosis: ruled out by the presence of typical cutaneous inflammatory signs, absence of calf induration, and presence of a portal of entry
Necrotizing fasciitis: excluded by the absence of signs of necrosis, crepitus, hemorrhagic bullae, or disproportionate pain
Erysipelas: although there is bacterial skin infection, the borders are poorly defined and there is deeper involvement, characterizing cellulitis
Stasis dermatitis: no history of significant venous insufficiency, and the presentation is acute with fever

Step-by-Step Coding

Criteria analysis:

Confirmed bacterial infection: Yes (clinical + laboratory)
Diffuse cutaneous involvement: Yes (erythema with poorly defined borders)
Signs of deep infection: Yes (cellulitis, not merely superficial)
Absence of necrosis or characteristics of fasciitis: Confirmed
Not a localized abscess: Confirmed
Not a superficial infection such as impetigo: Confirmed

Code selected: 1B70 - Bacterial cellulitis, erysipelas, or lymphangitis

Complete justification: Code 1B70 is appropriate because the patient presents with a classic presentation of acute bacterial cellulitis of the lower extremity, with all diagnostic criteria present. The infection is diffuse, involves the dermis and subcutaneous tissue, likely caused by streptococci or staphylococci (most common agents), with an identifiable portal of entry. There are no characteristics indicating the need for alternative codes such as necrotizing fasciitis (1B71), impetigo (1B72), or ecthyma (1B73).

Applicable complementary codes:

Type 2 diabetes mellitus (appropriate ICD-11 code for the underlying condition)
Obesity (appropriate ICD-11 code)
Foot wound (external cause code if relevant for statistics)

Documented therapeutic plan: Hospital admission for intravenous antibiotic therapy with first-generation cephalosporin, limb elevation, strict glycemic control, analgesia, and monitoring of clinical evolution. Reassessment in 24-48 hours to verify therapeutic response.

7. Related Codes and Differentiation

Within the Same Category

1B71: Necrotizing fasciitis

When to use 1B71 vs. 1B70: Use 1B71 when there is evidence of deep necrotizing infection involving fascia and muscles. Necrotizing fasciitis is a surgical emergency with high mortality if not treated promptly.

Main difference: The presence of progressive tissue necrosis, crepitus on palpation (indicating gas production), hemorrhagic bullae, pain disproportionate to physical examination, extremely rapid progression (hours), signs of severe systemic toxicity with hemodynamic instability, and cutaneous changes such as violaceous or grayish discoloration. Imaging studies may show gas in soft tissues. Treatment requires urgent surgical debridement in addition to antibiotics, unlike cellulitis (1B70) which typically responds to antibiotic therapy alone.

1B72: Impetigo

When to use 1B72 vs. 1B70: Use 1B72 for superficial epidermal infections, typically presenting with vesicles that rupture forming characteristic crusts.

Main difference: Impetigo is a superficial epidermal infection not involving deep dermis or subcutaneous tissue. It presents with vesicles or bullae that rapidly rupture, forming characteristic honey-colored crusts (meliceric crusts). It is highly contagious, more common in children, usually without significant systemic signs. There is no deep edema, intense heat, or prominent regional lymphadenopathy as in cellulitis. Treatment often consists of topical antibiotics for localized cases, whereas cellulitis requires systemic antibiotics.

1B73: Ecthyma

When to use 1B73 vs. 1B70: Use 1B73 when there are cutaneous ulcers with adherent crusts and raised borders, penetrating into the dermis.

Main difference: Ecthyma is characterized by well-defined ulcers, usually circular, with thick adherent crusts over an erythematous base. The lesions are localized and not diffuse as in cellulitis. Ecthyma penetrates more deeply than impetigo, but the lesions are discrete and circumscribed. It leaves scars after resolution, unlike cellulitis which typically resolves without scarring. It frequently occurs on the lower extremities of patients with poor hygiene, malnutrition, or immunocompromised status.

Differential Diagnoses

Deep venous thrombosis: May present with limb edema and erythema, but usually without significant fever or leukocytosis, with calf induration and positive Homans sign. Doppler ultrasound differentiates.

Stasis dermatitis: Chronic bilateral erythema on lower extremities, associated with venous insufficiency, with pigmentation changes and absence of fever or systemic signs.

Erythema nodosum: Painful subcutaneous nodules, usually bilateral on anterior leg surfaces, without diffuse erythema or high fever.

Acute gout: When affecting the ankle or foot, may mimic cellulitis, but presents with intense joint pain, history of hyperuricemia, and response to anti-inflammatory agents.

Insect bite with local reaction: Clear history of bite, localized lesion without significant progression, usually without fever or leukocytosis.

8. Differences with ICD-10

In ICD-10, bacterial skin infections were coded primarily under codes L00-L08, with cellulitis and acute lymphangitis coded as L03.

Equivalent ICD-10 codes:

L03.0: Cellulitis of fingers and toes
L03.1: Cellulitis of other parts of limbs
L03.2: Cellulitis of face
L03.3: Cellulitis of trunk
L03.8: Cellulitis of other sites
L03.9: Cellulitis of unspecified site

Major changes in ICD-11:

ICD-11 introduces a more logical and integrated structure, grouping cellulitis, erysipelas, and bacterial lymphangitis under a single code (1B70) within the category of pyogenic bacterial infections. This approach recognizes that these conditions represent a continuous spectrum of bacterial skin infection with similar pathogenic mechanisms.

In ICD-10, erysipelas had a separate code (A46), classified among bacterial diseases, while cellulitis was in the chapter of skin diseases. ICD-11 corrects this fragmentation, bringing related conditions together in a coherent category.

The hierarchical structure of ICD-11 is clearer, facilitating navigation and code selection. The system allows greater specificity through extensions and qualifiers, when necessary, while maintaining simplicity in basic coding.

Practical impact:

For healthcare professionals, the transition means familiarization with a new code structure, but with gains in logic and consistency. Health information systems require updates for ICD-11 compatibility.

Analysis of historical data requires mapping between ICD-10 and ICD-11, a process facilitated by official correspondence tables. Longitudinal epidemiological studies should consider changes in classification when interpreting temporal trends.

For management and reimbursement, the transition may require updates to protocols and payment systems, but greater clarity in coding tends to reduce ambiguities and administrative disputes.

9. Frequently Asked Questions

1. How is cellulitis, erysipelas, or bacterial lymphangitis diagnosed?

The diagnosis is primarily clinical, based on history and physical examination. The physician evaluates local signs (erythema, edema, warmth, pain) and systemic signs (fever, malaise). Laboratory tests such as complete blood count and inflammatory markers (C-reactive protein) support the diagnosis, but are not mandatory in typical cases. Blood cultures are recommended in severe cases or when signs of sepsis are present. Skin cultures are generally not necessary, except when there is purulent drainage. Imaging studies (ultrasound, computed tomography) are reserved for atypical cases or when complications such as deep abscess or necrotizing fasciitis are suspected.

2. Is treatment available in public health systems?

Yes, treatment of cellulitis, erysipelas, and bacterial lymphangitis is widely available in public health systems worldwide. The antibiotics used (penicillins, cephalosporins, macrolides) are on the World Health Organization's list of essential medicines and are generally accessible. Mild cases can be treated on an outpatient basis with oral antibiotics, while moderate to severe cases require hospitalization for intravenous antibiotic therapy. Most health systems cover both outpatient and hospital treatment for these infections.

3. How long does treatment last?

The typical duration of antibiotic treatment is 5 to 14 days, depending on severity and clinical response. Mild cases may respond adequately to 5-7 days of oral antibiotics, while more severe cases may require 10-14 days, starting with intravenous therapy followed by transition to oral route after clinical improvement. Response is generally observed within 24-48 hours after initiation of appropriate treatment. Signs of improvement include fever reduction, decreased area of erythema, and pain reduction. Patients with risk factors (diabetes, immunodeficiency) may require longer treatment. It is essential to complete the prescribed course even after symptom improvement to prevent recurrence and bacterial resistance.

4. Can this code be used in medical certificates?

Yes, code 1B70 can and should be used in medical certificates when appropriate. Medical certificates frequently require ICD coding to justify work absence or other administrative needs. Cellulitis, erysipelas, and bacterial lymphangitis are conditions that commonly justify temporary absence, especially when affecting lower limbs (impairing ambulation) or when there are significant systemic signs. The period of absence varies according to severity, location, and patient occupation, but typically ranges from 3 to 14 days. Documentation should include the ICD-11 code, description of the condition, and justification for the absence.

5. Can cellulitis become a serious infection?

Yes, although most cases respond well to treatment, cellulitis can progress to serious complications if not treated appropriately. Complications include abscess formation, necrotizing fasciitis, bacteremia, and sepsis. Patients with diabetes, immunodeficiency, peripheral vascular disease, or advanced age have a higher risk of complications. Warning signs include rapid progression despite antibiotics, disproportionate pain, hemorrhagic bullae, altered level of consciousness, or hemodynamic instability. In these cases, urgent reevaluation and possible hospital admission are necessary. Mortality is low in uncomplicated cellulitis, but increases significantly if there is progression to necrotizing fasciitis or sepsis.

6. What are the risk factors for developing cellulitis?

Several factors increase the risk of cellulitis: disruption of skin barrier (wounds, ulcers, fissures, dermatoses), obesity, diabetes mellitus, chronic venous insufficiency, lymphedema (including after lymphadenectomy surgery), immunodeficiency (HIV, use of immunosuppressants, chemotherapy), chronic liver or kidney disease, injection drug use, and previous history of cellulitis. Conditions that cause chronic edema of the lower limbs are particularly important. Identifying and managing risk factors is essential to prevent recurrences, which occur in a significant proportion of patients.

7. Is culture necessary before starting antibiotics?

In most cases of uncomplicated cellulitis, cultures are not necessary before initiating empiric treatment. The diagnosis is clinical and the most likely pathogens (streptococci and staphylococci) are predictable, allowing appropriate empiric antibiotic selection. Blood cultures should be considered in patients with severe systemic signs, immunocompromised patients, or when there is failure to respond to initial treatment. Culture of aspirate or skin biopsy is rarely necessary, reserved for atypical, recurrent cases, or those not responding to multiple antibiotic regimens. In areas with high prevalence of methicillin-resistant Staphylococcus aureus (MRSA), adjustments in empiric selection may be necessary.

8. How to prevent cellulitis recurrences?

Prevention of recurrences involves multiple strategies: treatment of portals of entry (tinea pedis, heel fissures, eczema), skin hygiene and hydration care, lymphedema management (compression stockings, lymphatic drainage), strict diabetes control, weight loss in obese patients, and treatment of venous insufficiency. In patients with multiple recurrences (generally defined as three or more episodes per year), long-term antibiotic prophylaxis with penicillin or erythromycin may be considered, although it should be individualized considering risks of bacterial resistance and adverse effects. Patient education on early recognition of recurrence signs and immediate medical attention is also fundamental.

Conclusion

Appropriate coding of cellulitis, erysipelas, and bacterial lymphangitis under ICD-11 code 1B70 is essential for accurate clinical documentation, effective communication among health professionals, reliable epidemiological analysis, and appropriate administrative management. Understanding when to use this code, differentiating it from related conditions, and properly documenting clinical findings are fundamental competencies for health professionals in the ICD-11 era. This guide provides a solid foundation for correct coding of these important bacterial skin infections, contributing to improvement in the quality of global health data.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Cellulitis, Erysipelas, or Bacterial Lymphangitis

Compartir